This month’s Going on Trial newsletter explores a new tool for communicating with clinical trial participants and their families, among other drug development news.

This month’s Going on Trial newsletter explores how eye tracking might be used beyond helping with diagnosis, among other drug development news.

This month’s Going on Trial newsletter dives into an electroencephalography biomarker that could track the efficacy of treatments for dup15q and Angelman syndromes, among other drug development news.

This month’s Going on Trial newsletter explores how organ-on-a-chip models could smooth the transition from preclinical to clinical trials, among other drug development news.

This month’s newsletter looks at the early safety data from the first gene therapy trial for Rett syndrome, among other drug development news.

This month’s issue of Going on Trial takes a sneak peek at some early null results from a small trial of a cannabidiol-based drug for autism, among other recent drug developments.

This month’s issue of the Going on Trial newsletter explores why it’s more fun to have a beer with friends than by yourself — and how that informs an ongoing clinical trial for autism.

This month’s issue of the Going on Trial newsletter examines personalized therapies for rare conditions, Acadia’s new drug for Rett syndrome and developments in a cord-blood program, among other autism-related drug trial news.

This month’s newsletter takes a close look at the orphan drug program in the United States, several cannabis-based therapies and a secondary analysis of bumetanide, among other new developments in autism-related drug trials.

Going on Trial rounds up new developments in autism-related drug trials. This month we’re revisiting decade-old data from a trial of arbaclofen for fragile X syndrome and looking into a new implant-based approach to quelling seizures, among other treatment strategies.